AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27823876
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL intranasal midazolam
Trial: 27823876
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL intranasal midazolam
Trial: 25946554
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg every 2 weeks after a loading dose)
Trial: 25946554
Drug: Methotrexate (7.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (7.5-25 mg/wk)
Trial: 23394621
Drug: Ceftizoxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime administered pre-incision
Trial: 23394621
Drug: Ceftizoxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime administered post-clamping of the umbilical cord
Trial: 19814948
Drug: Increased-dose selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased-dose selective serotonin reuptake inhibitor (SSRI)
Trial: 19814948
Drug: Medication optimization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication optimization with SSRI plus clonazepam
Trial: 10806822
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol (100 mg)
Trial: 28438471
Drug: Actovegin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin treatment
Trial: 25523883
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (500 mg, twice daily for 8 weeks)
Trial: 21333021
Drug: FITNET (web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FITNET (web-based cognitive behavioural therapy)
Trial: 9053465
Drug: Low-dose filgrastim
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose filgrastim (50 microg/m2)
Trial: 29681235
Drug: Melatonin niosomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin niosomes (MN) gel, 2.5 mg, 5 mg, and 10 mg, topically applied
Trial: 29681235
Drug: Melatonin gel
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin gel (control)
Trial: 26621513
Drug: Computerised cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised cognitive behaviour therapy (cCBT)
Trial: 11257563
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG): 2 mg/kg BN 52021, administered intravenously 120 mg BN 52021 before reperfusion.
Trial: 11257563
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG): 10 mg/kg BN 52021, administered intravenously 600 mg BN 52021 before reperfusion.
Trial: 11257563
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG): Placebo administered before reperfusion.
Trial: 7506166
Drug: nimesulide 200
RxNorm normalized name: nimesulide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide 200 mg/day
Trial: 7506166
Drug: ketoprofen 150
RxNorm normalized name: ketoprofen 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketoprofen 150 mg/day
Trial: 2872807
Drug: Terazosin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin plus diuretic
Trial: 2872807
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus diuretic
Trial: 24086334
Drug: Azithromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (30 mg/kg single dose)
Trial: 22185601
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with heterologous vaccine (HE)
Trial: 22185601
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with homologous inactivated vaccine (HO)
Trial: 18337638
Drug: Caffeine (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.75 mg/kg) 3 times daily for 4 consecutive weeks
Trial: 9152821
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine dry powder spray at dressing changes
Trial: 9152821
Drug: No povidone
RxNorm normalized name: Povidone
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No povidone iodine spray (control group)
Trial: 26088909
Drug: Intensive control
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive control (target BG range of 4.5‐6.0 mmol/L)
Trial: 26088909
Drug: Conventional control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional control (target BG <10 mmol/L)
Trial: 21525248
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g L-leucine with each main meal (7.5 g/d)
Trial: 19220847
Drug: Nanocrystalline hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocrystalline hydroxyapatite silica gel (Group 1, 3 months healing)
Trial: 19220847
Drug: Nanocrystalline hydroxyapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocrystalline hydroxyapatite silica gel (Group 2, 6 months healing)
Trial: 12682468
Drug: Ibutilide 0.008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide 0.008 mg/kg body weight over 10 mins; if needed, amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Trial: 12682468
Drug: Amiodarone 5
RxNorm normalized name: amiodarone 50 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Trial: 10937764
Drug: Iodixanol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (320 mg I/ml)
Trial: 11104872
Drug: Ioxaglate (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioxaglate (320 mg I/ml)
Trial: 8613058
Drug: UDCA (13-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (13-15 mg.kg-1.day-1)
Trial: 1446728
Drug: GM-CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF plus AraC (20 mg/m2/d s.c.)
Trial: 3001664
Drug: ACTH 4-9
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-9 analog (5 mg)
Trial: 3001664
Drug: ACTH 4-9
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-9 analog (10 mg)
Trial: 3001664
Drug: ACTH 4-9
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-9 analog (20 mg)
Trial: 11923794
Drug: Bivalirudin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin 1.0 mg/kg bolus followed by a 4-hour infusion at 2.5 mg/kg/h
Trial: 11923794
Drug: Bivalirudin 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin 0.75 mg/kg bolus followed by a 4-hour infusion at 1.75 mg/kg
Trial: 11923794
Drug: Heparin 60
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin 60 U/kg bolus
Trial: 11923794
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including bivalirudin and heparin) with eptifibatide
Trial: 11923794
Drug: Bivalirudin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin and Heparin
Trial: 26762374
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol enriched soy-based yogurts (4.0 g plant stanols/d)
Trial: 23180952
Drug: Probiotics (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to triple therapy
Trial: 23180952
Drug: Probiotics (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks after triple therapy
Trial: 23180952
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, and amoxicillin 1000 mg bid)
Trial: 23180952
Drug: Probiotics (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to or after triple therapy
Trial: 19925528
Drug: Cilnidipine 10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine 10-20 mg once daily for 4 weeks
Trial: 19925528
Drug: Losartan 50-100
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50-100 mg once daily for 4 weeks
Trial: 28025969
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation (valsartan tablet)
Trial: 28025969
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (valsartan tablet)
Trial: 11140029
Drug: Competency-based primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Competency-based primary care drug therapy (PCDT) training programme
Trial: 3325318
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline capsules
Trial: 3325318
Drug: Standard slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard slow-release theophylline tablets
Trial: 27714649
Drug: Telephone-delivered stepped
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Telephone-delivered stepped collaborative care (CC)
Trial: 23232039
Drug: Tobramycin nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI eFlow(®) rapid nebuliser
Trial: 23232039
Drug: Tobramycin nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI LC Plus(®) nebuliser
Trial: 23232039
Drug: Tobramycin nebuliser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin nebuliser solution 300 mg/4 mL (TNS4)
Trial: 21383098
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 150 mg maraviroc b.i.d. with darunavir-ritonavir
Trial: 21383098
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 300 mg maraviroc b.i.d. with etravirine
Trial: 21383098
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of 150 mg maraviroc b.i.d. with etravirine-darunavir-ritonavir
Trial: 11217680
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or reference drugs
Trial: 9051392
Drug: Training plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training plus BCAA supplement
Trial: 9051392
Drug: Sedentary plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedentary plus BCAA supplement
Trial: 8364776
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (CBS) 300 mg 1 hour before each meal and at bedtime (n = 16)
Trial: 8364776
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg bid (n = 12)
Trial: 8364776
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg b.i.d.) plus metronidazole (250 mg t.i.d; n = 14)
Trial: 29195025
Drug: CLM +
RxNorm normalized name: Chlorpheniramine
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLM + BUD (clarithromycin 0.25 g/d and budesonide 256 μg/d)
Trial: 29195025
Drug: BUD (budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD (budesonide 256 μg/d)
Trial: 18241260
Drug: DHA 5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA 5.4 g daily (n = 21)
Trial: 15931018
Drug: Relaxation Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relaxation Response (RR) intervention for 15 weeks, practicing techniques at home twice a day
Trial: 3558936
Drug: Heparin-bonded pulmonary-artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded pulmonary-artery catheters
Trial: 3558936
Drug: Non-heparin-bonded pulmonary-artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-heparin-bonded pulmonary-artery catheters
Trial: 31708063
Drug: Star rating-targeted
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Star rating-targeted medications (oral antidiabetic medications, RAS antagonists, statins)
Trial: 31708063
Drug: Nontargeted antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nontargeted antihypertensive and antihyperlipidemic medications
Trial: 25559252
Drug: Discontinued-incentive condition
RxNorm normalized name: Entex HC Discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued-incentive condition receiving weekly incentives during fall semester 2011, and no incentives during spring semester 2012
Trial: 25559252
Drug: Continued-incentive condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued-incentive condition receiving weekly incentives during fall semester, and incentives on a variable-interval schedule during spring semester
Trial: 8891015
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Micanol and UVB therapy
Trial: 8891015
Drug: Dithranol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol treatment (previous studies)
Trial: 2000823
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg beta-carotene/d
Trial: 2000823
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg beta-carotene/d
Trial: 2000823
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg beta-carotene/d
Trial: 2000823
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg beta-carotene/d
Trial: 27215949
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) + Attention Control (AC)
Trial: 27215949
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) + COPD Education (COPD-ED)
Trial: 25057878
Drug: Maternal levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal levothyroxine therapy
Trial: 15841764
Drug: Commercial MCD
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial MCD and porridge (CC group)
Trial: 15841764
Drug: Infants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants with Hb < 110 g/l at 12 months
Trial: 15841764
Drug: Infants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infants with S-Zn < 10.7 pmol/l at 12 months
Trial: 9731046
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine and mitoxantrone as consolidation in study 04/89
Trial: 8858275
Drug: Mefloquine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (250 mg on Days 1, 2, 3, 8, 15, 22, and 29)
Trial: 8858275
Drug: Alcohol (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (sustained blood concentration of about 0.35 mg.ml-1)
Trial: 31294473
Drug: Modifying the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modifying the prosthesis to allow for better oral hygiene (test group)
Trial: 31294473
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without modifying the prosthesis (control group)
Trial: 22914806
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (ACT = 250 s)
Trial: 22914806
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (full heparin dose, ACT = 420 s)
Trial: 19845769
Drug: Oxycodone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone with A118G variant allele
Trial: 19845769
Drug: Oxycodone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone with C3435T variant allele
Trial: 19845769
Drug: Oxycodone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone with G2677T/A variant allele
Trial: 15775730
Drug: Exercise (weekly)
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Exercise (weekly)
Trial: 10613346
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (20 mg/day)
Trial: 7603812
Drug: WI79‐9 virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WI79‐9 virus vaccine (10^7.3 plaque‐forming units in three oral doses separated by 2 months)
Trial: 2262643
Drug: Ryegrass allergen
RxNorm normalized name: English ryegrass allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryegrass allergen (incremental doses applied topically to one eye)
Trial: 2262643
Drug: Ryegrass allergen
RxNorm normalized name: English ryegrass allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ryegrass allergen (320,000 BU/ml)
Trial: 31118
Drug: Heparin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin + Urokinase (UK)
Trial: 31100514
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 16–32 mg/kg/d infusion for 6 days
Trial: 23134570
Drug: 2009 pandemic
RxNorm normalized name: Influenza A virus H1 2009 pandemic Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 pandemic (H1N1) vaccine containing 7.5 μg haemagglutinin (HA)
Trial: 23134570
Drug: 2009 pandemic
RxNorm normalized name: Influenza A virus H1 2009 pandemic Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 pandemic (H1N1) vaccine containing 15 μg haemagglutinin (HA)
Trial: 11305513
Drug: Tetanus toxoid
RxNorm normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus toxoid vaccine (1 ml, 6 Lf units)
Trial: 19081697
Drug: MDI/spacer combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI/spacer combination
Trial: 16409529
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml x kg(‐1) x h(‐1) of lactated Ringer's solution (superhydration group)
Trial: 16409529
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml x kg(‐1) x h(‐1) of lactated Ringer's solution (control group)
Trial: 3292596
Drug: Prostacyclin (epoprostenol)
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin (epoprostenol) infused intravenously at a dose of up to 5 ng/kg/min for 72 hours with a tapering off period for the last 12 hours.
Trial: 3292596
Drug: Placebo infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infused intravenously for the same duration and dosage as prostacyclin.
Trial: 30848576
Drug: M2000 (β-D-Mannuronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2000 (β-D-Mannuronic Acid), 500 mg two times a day for 6-8 weeks
Trial: 26115578
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 80 μg/day
Trial: 22000795
Drug: 1-injection group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-injection group (20 mL of 0.75% bupivacaine and 10 mL 98% alcohol)
Trial: 22000795
Drug: 2-injection group
RxNorm normalized name: meningococcal group B vaccine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-injection group (20 mL of 0.75% bupivacaine and 10 mL 98% alcohol)
Trial: 10740548
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml-1 in 0.9% glucose solution
Trial: 10740548
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml-1 in 8% glucose solution
Trial: 27348903
Drug: YANG's pricking‐cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YANG's pricking‐cupping therapy
Trial: 25308231
Drug: VK1 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VK1 solution